Cyteir Therapeutics Revenue and Competitors

Boston, MA USA

Location

$156.7M

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • Cyteir Therapeutics's estimated annual revenue is currently $3.3M per year.(i)
  • Cyteir Therapeutics's estimated revenue per employee is $147,993
  • Cyteir Therapeutics's total funding is $156.7M.
  • Cyteir Therapeutics's current valuation is $216.5M. (January 2022)

Employee Data

  • Cyteir Therapeutics has 22 Employees.(i)
  • Cyteir Therapeutics grew their employee count by -60% last year.

Cyteir Therapeutics's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
VP Clinical OperationsReveal Email/Phone
3
VP, Clinical OperationsReveal Email/Phone
4
ControllerReveal Email/Phone
5
Associate DirectorReveal Email/Phone
6
Director, Process ChemistryReveal Email/Phone
7
Senior Director, Head Translational ResearchReveal Email/Phone
8
Chief Scientific OfficerReveal Email/Phone
9
Senior Director, Head Analytical ChemistryReveal Email/Phone
10
General CounselReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1M176%N/AN/A
#2
$13.4M13110%N/AN/A
#3
$42.8M3360%N/AN/A
#4
$7.8M760%N/AN/A
#5
$8.2M803%N/AN/A
#6
$0.1M6-25%$1.9MN/A
#7
$5.7M6211%N/AN/A
#8
$0.9M140%N/AN/A
#9
$25.2M2257%N/AN/A
#10
$6.3M7113%$1.7MN/A
Add Company

What Is Cyteir Therapeutics?

Through a unique cancer treatment approach, Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

keywords:N/A

$156.7M

Total Funding

22

Number of Employees

$3.3M

Revenue (est)

-60%

Employee Growth %

$216.5M

Valuation

N/A

Accelerator

Cyteir Therapeutics News

2022-04-17 - Cyteir Therapeutics to Host Virtual Research and ...

(“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will...

2022-03-22 - Cyteir Therapeutics Reports Fourth Quarter and Full Year ...

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies...

2021-06-04 - Cyteir Therapeutics Announces Presentation of First-in-Human Phase 1/2 Study of CYT-0851

LEXINGTON, Mass., June 4, 2021 /PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the presentation of an interim analysis of the Phase 1 portion of a first-in-human Phase 1/2 study of CYT- ...

2021-02-11 - Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program

LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing. The company will use the new funds to advance ...

2021-02-11 - Cyteir Therapeutics Secures $80 Million in Series C

Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series C financing. The company will use the new funds to advance its lead compound, the first-in-class inhibitor of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A22-12%N/A
#2
$3.4M22-59%N/A
#3
$3.8M22-12%N/A
#4
$3.4M225%N/A
#5
$3.2M22-8%N/A